Will there ever be a European drug pricing and reimbursement agency? M. F. Drummond Editorial Pages: 67 - 69
Modeling the cost-effectiveness and budgetary impact for subpopulations M. J. C. NuijtenJ. KosaP. Engelfriet Original Papers Pages: 70 - 78
Public health insurance Pareto-efficient allocative improvements through differentiated copayment rates R. Osterkamp Original Papers Pages: 79 - 84
Length of hospital stay and associated costs for olanzapine vs. haloperidol in the treatment of schizophrenia relapse in Germany A. SpannheimerU. ReitbergerM. Lothgren Original Papers Pages: 85 - 89
Theory verses empiricism in health economics J. F. P. BridgesP. Haywood Original Papers Pages: 90 - 95
Influence of surgical and treatment choices on the cost of breast cancer care C. J. BradleyC. GivenJ. Gardiner Original Papers Pages: 96 - 101
Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados Département, France V. BouvierJ.-M. ReaudG. Launoy Original Papers Pages: 102 - 106
Health-based risk adjustment Improving the pharmacy-based cost group L. M. LamersR. C. J. A. Vliet Original Papers Pages: 107 - 114
Metal on metal hip resurfacing arthroplasty L. McKenzieL. ValeK. McCormack Original Papers Pages: 122 - 129
Cost-effectiveness analysis of two strategies for typing unrelated donors for bone marrow transplantation in France D. BercheryL. MolinierA. Cambon-Thomsen Original Papers Pages: 130 - 137